baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. CALL 06/24 4AB/ DE000HC3LFP6 /

02/05/2024 13:11:05	Chg.-	Bid02/05/2024	Ask-	Underlying	Strike price	Expiration date	Option type
0.0010EUR	-	0.0010 Bid Size: 10,000	- Ask Size: -	ABBVIE INC. D...	200.00 -	19/06/2024	Call

GlobeNewswire 13:26 CEREVEL THERAPEUTICS ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation (Nasdaq: C...

GlobeNewswire 13:10 Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million

GlobeNewswire 25/05 CERE (NASDAQ) ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law ...

GlobeNewswire 24/05 Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7...

GlobeNewswire 23/05 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...

GlobeNewswire 22/05 Over 130 Resident Dermatologists Receive In-Depth Cosmetic Training From Renowned ASDS Member Physic...

GlobeNewswire 22/05 Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $57...

GlobeNewswire 22/05 CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire 22/05 Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $57...

GlobeNewswire 22/05 Anavex Life Sciences Announces Expansion of Leadership Team

GlobeNewswire 22/05 OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treat...

GlobeNewswire 21/05 COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer

GlobeNewswire 21/05 BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by Ab...

GlobeNewswire 21/05 Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

GlobeNewswire 17/05 INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerev...

GlobeNewswire 16/05 CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire 16/05 Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

GlobeNewswire 14/05 CEREVEL THERAPEUTICS HOLDINGS, INC. (NASDAQ: CERE) INVESTIGATION ALERT: Is $45 per CERE Share Enough...

GlobeNewswire 14/05 Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

GlobeNewswire 14/05 Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...

GlobeNewswire 14/05 In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit

GlobeNewswire 13/05 Royalty Pharma to Present at Upcoming Investor Conferences

GlobeNewswire 11/05 SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LABP, DOMA, FXNC

GlobeNewswire 09/05 Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

GlobeNewswire 09/05 Royalty Pharma Reports First Quarter 2024 Results

UC WAR. CALL 06/24 4AB/ DE000HC3LFP6 /

If you wish to receive reply to your feedback, please provide your email address.